Group 1: Yishitong - Yishitong has made progress in several new material projects, including solid oxide battery (SOC) systems, high-purity quartz sand, bismuth stone, thermally conductive spherical alumina, and flame-retardant materials [1] - The SOC system project is progressing as planned, with the single battery pilot line operating stably, and the stack pilot production line expected to be completed by 2025 [1] - High-purity quartz sand's technical indicators and performance optimization have been completed, with plans to test in a single crystal factory by 2025 and establish a thousand-ton pilot line [1] - Bismuth stone shipments are expected to increase in 2024, with a slight decrease in price, and significant shipment growth anticipated in Q1 2025 [1] - The sales revenue of ceramic flame-retardant materials is increasing, with plans to expand into more application scenarios [1] Group 2: Desay Battery - Desay Battery anticipates uncertainties in the macroeconomic environment but aims to explore new markets and businesses for performance growth [2] - In 2024, revenue from smartphone battery business is expected to decline by 10.39%, influenced by both volume and price [2] - In Q1 2025, revenue from smartphone batteries is projected to grow by 8.97%, while wearable device batteries are expected to increase by 15.79% [2] - Revenue from electric tools, smart home, and mobility businesses is expected to grow by 24.37%, while energy storage business revenue is projected to decline by 14.86% [2] - The company plans to continue expanding production capacity in Vietnam, with expected revenue growth in Vietnam to double compared to last year [2] Group 3: Yahui Pharmaceutical - Yahui Pharmaceutical has made progress in the approval and commercialization of APL-1702, with the listing application accepted and review underway [3] - APL-2501 has completed multiple experiments, with IND submission expected by mid-2026, showing strong clinical competitive potential [3] - The company is targeting patients with strong willingness to pay for the initial positioning of Haikewei, gradually promoting blue light cystoscopy technology as a standard solution [3] - APL-2302 shows good pharmacokinetic characteristics and significant anti-tumor effects, having entered clinical research [3] - The company expects rapid revenue growth in 2024 and plans to upgrade its commercialization system in 2025, including hiring a Chief Commercial Officer and optimizing the organizational structure [3]